Table of Contents
Overview
New York, NY – June 25, 2025 – Global Newborn Screening Market size is expected to be worth around US$ 2.3 Billion by 2034 from US$ 1.1 Billion in 2024, growing at a CAGR of 7.5% during the forecast period from 2025 to 2034. In 2024, Asia Pacific led the market, achieving over 37.2% share with a revenue of US$ 0.4 Billion.
Newborn screening is a crucial public health program aimed at the early identification of rare but serious health conditions in infants. Conducted shortly after birth, this screening helps detect metabolic, genetic, hormonal, and functional disorders that may not be visible at birth but can cause severe health problems or developmental delays if left untreated.
The process typically involves a simple heel-prick blood test, hearing test, and sometimes a pulse oximetry test to check for heart defects. The blood sample is analyzed for a range of conditions including phenylketonuria (PKU), congenital hypothyroidism, cystic fibrosis, sickle cell disease, and severe combined immunodeficiency (SCID), among others. Early detection through newborn screening enables timely treatment and management, preventing long-term complications and improving outcomes.
In many countries, newborn screening is a mandatory part of postnatal care and is offered to all infants regardless of race, gender, or family health history. According to the U.S. Centers for Disease Control and Prevention (CDC), newborn screening identifies about 12,500 infants with serious conditions annually in the United States alone. As healthcare systems continue to evolve, newborn screening programs are being expanded to include more conditions and technologies. Ensuring universal access to this essential service remains a top priority for global health organizations to secure healthier futures for children worldwide.
Key Takeaways
- Market Size: The global newborn screening market is projected to reach approximately US$ 2.3 Billion by 2034, rising from US$ 1.1 Billion in 2024.
- Market Growth: The market is anticipated to expand at a compound annual growth rate (CAGR) of 7.5% during the forecast period 2025 to 2034.
- Product Analysis: The instruments segment accounted for 65.3% of total revenue in 2024, indicating a strong demand for advanced screening technologies and analytical platforms.
- Application Analysis: Tandem mass spectrometry emerged as the leading application, contributing 29.4% share of the overall market, reflecting its widespread use in detecting multiple disorders from a single test.
- Test Type Analysis: Among various test types, the dried blood spot (DBS) test dominated in 2024, capturing 46.7% of the global market share due to its efficiency, reliability, and ease of sample collection.
- Regional Analysis: Asia Pacific led the newborn screening market in 2024, securing 37.2% of the global share with a total revenue of approximately US$ 0.4 billion, driven by expanding healthcare infrastructure and rising awareness programs.
Segmentation Analysis
- Product Analysis: In 2024, instruments held the largest share of the newborn screening market at 65.3%, driven by technologies like tandem mass spectrometry (MS/MS), PCR systems, and immunoassay analyzers. These platforms offer high-throughput, automation, and precise detection of various disorders. Their dominance reflects ongoing innovation and support from regulatory bodies such as the CDC. The reagents segment, though smaller, is growing steadily due to rising test volumes and broader screening panels requiring assay kits and quality control materials.
- Technology Analysis: Tandem mass spectrometry led the technology segment in 2024 with a 29.4% market share, attributed to its accuracy and multiplex testing capability. Pulse oximetry remains essential for CCHD detection due to its affordability and noninvasive use. Enzyme-based assays are applied in metabolic disorder diagnosis, while DNA assays like PCR and NGS detect genetic mutations. Electrophoresis supports hemoglobinopathy screening. Other emerging tools, such as immunoassays and microfluidics, are gaining regulatory backing to improve screening precision and panel expansion.
- Test Type Analysis: The dry blood spot (DBS) test dominated the test type segment in 2024, accounting for 46.7% market share. Its popularity stems from minimal invasiveness, low sample requirements, and scalability. Pulse oximetry is widely used for CCHD screening due to rapid bedside use. Hearing screening, using OAE and ABR tests, is vital for early detection of hearing loss in newborns. Emerging segments include genetic and point-of-care assays, expected to grow with advancements in technology and reimbursement support.
Market Segments
By Product
- Instruments
- Reagents
By Technology
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme Based Assay
- DNA Assay
- Electrophoresis
- Others
By Test Type
- Dry Blood Spot Test
- CCHD
- Hearing Screen
Regional Analysis
In 2024, Asia Pacific emerged as the leading region in the global newborn screening market, accounting for over 37.2% of the total market share, with a valuation of approximately US$ 0.4 billion. This growth is driven by rising birth rates, improved healthcare access, and national screening initiatives in countries such as India and China. Government-backed programs have significantly enhanced early detection of genetic and metabolic disorders. In addition, increasing public awareness and investment in healthcare infrastructure across Southeast Asia are further contributing to market expansion.
Meanwhile, North America continues to represent a mature and technologically advanced segment of the newborn screening market. In 2024, the region maintained a strong market position, supported by mandatory screening regulations across the United States. According to the Centers for Disease Control and Prevention (CDC), all U.S. states conduct newborn screening for over 30 core conditions.
High levels of parental awareness, advanced laboratory capabilities, and trained clinical staff contribute to consistent demand. Strong involvement from public health agencies also ensures widespread coverage and adherence to standardized screening protocols, reinforcing North America’s role in early diagnostic interventions for newborn health.
Emerging Trends
- Expansion of Screening Panels: The Recommended Uniform Screening Panel (RUSP) in the United States has grown from screening 28 core conditions in 2006 to 36 by August 2022. This expansion ensures earlier detection of a wider range of treatable disorders, such as severe combined immunodeficiency and critical congenital heart disease.
- Point-of-Care Testing Adoption: Two conditions hearing loss and critical congenital heart disease are now screened at the point of care. This shift reduces time to diagnosis and allows immediate follow-up interventions before hospital discharge.
- Global Implementation Guidance: In March 2024, WHO released regional guidance for universal screening in South-East Asia, targeting hearing impairment, eye abnormalities, and neonatal jaundice. This effort aims to prevent disabilities by standardizing early testing protocols across multiple countries.
- Data-Driven Quality Improvement: The CDC’s ED3N pilot program is deploying a new data platform to enhance disease detection from dried blood spot samples. By leveraging advanced analytics, state programs can refine screening accuracy and expand their capacity to add new conditions.
Use Cases
- Metabolic and Genetic Disorder Detection: Approximately 4 million U.S. infants are screened each year, with about 12 500 diagnosed with a core condition nearly 1 in every 300 babies. Early treatment for disorders such as phenylketonuria and medium-chain acyl-CoA dehydrogenase deficiency can prevent severe disability.
- Hearing Loss Identification: Early Hearing Detection and Intervention (EHDI) programs now reach nearly all newborns nationwide. Over 98% of U.S. infants have access to standardized hearing screening, enabling prompt fitting of hearing devices and speech therapy when needed.
- Global Coverage in Low-Resource Settings: Globally, only about 28% of the world’s 140 million annual births approximately 40 million babies undergo some form of newborn screening. In Latin America (20 countries, 11 million births per year), around 50% of infants receive screening; in Asia Pacific, roughly 5 million babies are covered annually; and in the Middle East, about 7 million are tested each year.
- Immediate Clinical Decision Support: Point-of-care screening for critical congenital heart disease enables on-site pulse oximetry testing before hospital discharge. This use case has reduced late diagnoses by up to 50%, improving survival rates in the first weeks of life.
Conclusion
Newborn screening plays a vital role in safeguarding infant health by enabling the early detection and treatment of life-threatening conditions. With the global market projected to reach US$ 2.3 billion by 2034, growth is being driven by technological advancements, policy mandates, and rising awareness. Asia Pacific leads in adoption, while North America remains technologically advanced.
Expansion of screening panels, point-of-care diagnostics, and global policy support from organizations like the CDC and WHO are enhancing coverage and accuracy. Continued investment in infrastructure and universal access is essential to improve outcomes and reduce the burden of undiagnosed disorders worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
